Abstract 2169P
Background
The incidence of cancer increases with age, advanced age remains the most important risk factor for most cancers. According to epidemiological statistics, the probability of developing invasive cancer in each age group is highest in the 70 years and older group, reaching 1/4 to 1/3. Immunotherapy is increasingly indicated for solid tumors, but toxicity and efficacy in older adults [age ≥70 years(y)] are unknown. The purpose of this study was to determine age-based differences in OS and treatment-related side effects.
Methods
This is a multicenter retrospective cohort study of patients with advanced cancer. Patients who received ≥1 dose of IO from January 1, 2019 to October 1, 2021 at three centers in China were collected to extract important information from the medical records. The primary outcome was PFS and OS since the start of the first IO treatment, compared between patients of different ages.
Results
We included 302 patients aged 60 to 99 years, of whom 157 were 60-69 years (younger group,YG) and 145 were 70 years and older (older group,OG), including 31 patients aged 80 years and older (senior group,SG). In all age groups, the proportion of patients in the OG group treated with immune combination therapy was relatively less than in the two younger age groups. Adverse event (AE) associated with immunotherapy was not higher in the older group than in the relatively younger cohort. there were no statistical differences in PFS and OS between the YG and OG groups, with median PFS of 12 months vs. 10 months, P=0.5465; median OS NA vs. 32 months, P=0.1429. Further subgroup analysis showed that the SG group had a median PFS of 10 months and median OS of 23 months, which was also not statistically different compared with other groups.
Table: 2169P
Immunotherapy-related adverse events
| N (%) of 60-69 N=157 | N (%) of 70 and older cohort N=145 | P | |
| Any grade toxicity | 31.8% | 37.9% | 0.2788 |
| >=Grade 3 toxicity | 10.8% | 9.0% | 0.7010 |
| >=Grade 3 toxicity types | |||
| Dermatitis | 1.9% | 4.1% | 0.2555 |
| Colitis | 2.5% | 2.1% | 0.7823 |
| Abnormal thyroid function | 1.9% | 2.8% | 0.7140 |
| Hepatitis | 3.8% | 1.4% | 0.2856 |
| Pneumonitis | 4.5% | 2.8% | 0.5449 |
| Other | 1.3% | 0.7% | 0.6049 |
Conclusions
IO-based therapy is relatively safe in elderly patients and provides a survival benefit in this group, allowing for prospective clinical studies in older patients to further determine the value of immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2247P - Expression of PD-L1 on circulating epithelial tumor cells (CETCs) in men with primary non-metastatic prostate cancer
Presenter: Dorothea Schott
Session: Poster session 07
2248P - Capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer (PANDORA trial): Molecular profiling and translational results
Presenter: Stefano Tamberi
Session: Poster session 07
2249P - Mitigation of tumor microenvironment-mediated immunosuppression using a PD1-41BB switch protein with optimal affinity tcrs for first-in-class, 3rd generation TCR-T therapies
Presenter: Kirsty Crame
Session: Poster session 07
2250P - Exploring tumor microenvironment in lung cancer through patient-derived 3D models
Presenter: NORA JUCIUTE
Session: Poster session 07
2251P - The genomic landscape of radiotherapy-induced breast angiosarcoma: An alleanza contro il cancro (ACC) initiative for an unmet need in rare tumors
Presenter: Lorenzo Ferrando
Session: Poster session 07